home / stock / nvo / nvo articles

NVO Articles, Novo Nordisk A/S - From 01/19/24

Stock Information
Company Name: Novo Nordisk A/S
Stock Symbol: NVO
Market: NYSE
Website: novonordisk.com
Menu
NVO NVO Quote NVO Short NVO News NVO Articles NVO Message Board
Get NVO Alerts

News, Short Squeeze, Breakout and More Instantly...
Weightloss Drugs Ozempic And Wegovy's Success Sets Novo Nordisk's Owner To Utilize Dividend Windfall For Strategic Investments | Benzinga

In a recent interview, Kasim Kutay, Chief Executive Officer of Novo Holdings, announced the company’s ambitious plans for further a...
FDA Finds No Evidence Weight-Loss Drugs Cause Suicidal Thoughts | Benzinga

Following a preliminary review, the U.S. Food and Drug Administration found no evidence that weight-loss drugs cause suicidal thoughts. What To Kno...

Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo and Lilly's Dominance | Benzinga

Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positionin...

Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance | Benzinga

Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positionin...
P/E Ratio Insights for Novo Nordisk | Benzinga

In the current session, the stock is trading at $108.78, after a 0.10% spike. Over the past month, Novo Nordisk Inc. (NYSE:NVO) stock increased by ...

Analyst Assesses Cell-Programming Focused Ginkgo Bioworks' Positioning Amid Revenue Surge, Program Adjustments | Benzinga

Wednesday, Ginkgo Bioworks Holdings Inc (NYSE: DNA) released preliminary FY23 sales of $250 million-$260 million, compared to the consens...

Bring On The Competition In Obesity Drugs: Novo Nordisk CEO Optimistic About Prolonged Patient Adherence to Obesity Drug Wegovy | Benzinga

Lars Fruergaard Jorgensen, CEO of Novo Nordisk A/S (NYSE: NVO), shared insights during the JPMorgan Healthcare conference, highlighting W...
Pfizer's Aggressive Stance In Obesity Drugs: CEO Albert Bourla Confirms Bold Bet Despite Prior Drug Hurdles | Benzinga

Monday, at the JP Morgan Healthcare Conference, Pfizer Inc (NYSE: PFE) CEO Albert Bourla expressed that the company is det...

Ozempic Users Might Experience Caloric Intake Rise Post-Discontinuation: Survey | Benzinga

Deutsche Bank has recently conducted a survey suggesting that patients using Novo Nordisk A/S (NYSE:NVO) weight loss medication, Ozempic, may incre...

Wegovy and Ozempic Maker Novo Nordisk Shares Data From Phase 3 Diabetes Study Of Semaglutide/Insulin Containing Candidate | Benzinga

Novo Nordisk A/S (NYSE: NVO) announced topline results from the COMBINE 3 phase 3a trial of once-weekly IcoSema, a fixed-ratio combi...
Previous 10 Next 10